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Abstract
Neocarzinostain (NCS) was first used by Hiraki and his colleagues for induction chemother-
apy in acute leukemia. This new anti-tumor agent is a polypeptide with a high molecular weight
of 10,700 daltons. Anti-NCS antibody was produced in rabbits administered NCS intramuscularly
with or without adjuvant. The production of anti-NCS antibody in patients treated with NCS was
investigated. Forty three leukemia cases of various types were examined totally 65 times. Two
mg of NCS for four consecutive days by intravenous drip infusion followed by 7 to 10 days of
pause was repeatedly administered. The total amounts ranged 8 to 174 mg and the total periods
4 to 87 days. The methods used to measure the antibody titer are the passive hemagglutination
(PHA) test on microplate and the passive cutaneous anaphylaxis (PCA) reaction in guinea pigs.
The sera of all patients showed only non-specific agglutination at less than 2(3) dilution by PHA
test, and to confirm these results four patient sera were tested by PCA reaction. The production of
anti-NCS antibody was not detected in patients by PHA test and PCA reaction. The anaphylactic
reaction and other adverse reactions due to anti-NCS adtibody production were not demonstrated
in patients. Anti-NCS antibody was not detected by these experiments in the dose schedule ad-
ministered.
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Abstract. Neocarzinostatin (NCS) was first used by Hiraki and his
colleagues for induction chemotherapy in acute leukemia. This new
anti-tumor agent is a polypeptide with a high molecular weight of
10,700 daltons. Anti-NCS antibody was produced in rabbits admini-
stered NCS intramuscularly with or without adjuvant. The production
of anti.NCS antibody in patients treated with NCS was investigated.
Forty three leukemia cases of various types were examined totally 65
times. Two mg of NCS for four consecutive days by intravenous drip
infusion followed by 7 to 10 days of pause was repeatedly administered.
The total amounts ranged 8 to 174 mg and the total periods 4 to 87 days.
The methods used to measure the antibody titer are the passive hem-
agglutination (PHA) test on microplate and the passive cutaneous
anaphylaxis (PCA) reaction in guinea pigs. The sera of all patients
showed only non-specific agglutination at less than 23 dilution by PHA
test, and to confirm these results four patient sera were tested by PCA
reaction. The production of anti-NCS antibody was not detected in
patients by PHA test and PCA reaction. The anaphylactic reaction
and other adverse reactions due to anti-NCS antibody production
were not demonstrated in patients. Anti-NCS antibody was not
detected by these experiments in the dose schedule administered.
Neocarzinostatin (NCS) is an anti-tumor antibiotic, which was first iso-
lated from culture filtrate of Streptomyces carzinostaticus by Ishida et al. in 1956
(1). This agent has been chemically proved to be an acidic single-chained
polypeptide with molecular weight of 10,700, consisted of 109 L-amino acids of
18 kinds (2).
Since 1972, NCS has been applied for the first time by Hiraki et al. (3) for
the induction therapy of human acute leukemia, and its anti-leukemic effect
has been evaluated and proved to be excellent (4).
Because NCS has enough large size of molecular weight to produce the
antibody, the antigenicity of NCS has been demonstrared by Mukojima et al.
(5) and by Tsujino et al. (6) in their animal experiments.
Investigation of the anti-NCS antibody in leukemia patients administered
with NCS is considered to be important in preventing the adverse reactions of
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NCS and in antIcIpating the loss of therapeutic effectiveness of this agent.
Therefore, first, the anti-NCS antibody was produced in rabbits. Then, the
leukemia patients' sera were investigated by the passive hemagglutination
(PHA) test to search the anti-NCS antibody, and the questionable sera were
confirmed by the passive cutaneous anaphylaxis (peA) reaction in guinea pigs
to rule out non-specific rea.ctions.
MATERIALS AND METHODS
(1) Method of the anti-NCS antibody production in rabbits.
Rabbits, weighing 2.4-3.1 kg, were divided into 3 groups, consisted of 2 in
each.
NCS, 0.4-0.6mg (as shown in Table 1) was thoroughly homogenized with
T ABLE I METHOD OF THE ANTI-NCS ANTIBODY PRODUCTION IN RABBITS
serum
Group I (#1, #2)
NCS (mg) +
Freund's complete
adjuvant; 1. M.
1
0.4mg
2w 1
0.5mg
2w 1~ 1~ 1-lw-.n.
0.6mg 0.5mg 0.5mg
Group II (#3, #4)
NCS (0. I mg) +
Normal Saline 1. M.
Group III (#5, #6)
NCS (O.lmg) 1. V.
4 days
1111~ 1111~ 1111~ 1111~ 1111 ~.n.
serum
4 dayS
1111~ 1111~ 1111~ 1111~ 1111 ~.n.
serum
the same amount of Freund's complete adjuvant (Difco Laboratories), and this
mixture was intramuscularly injected for sensitization in group I. The sensi-
tizing procedures were done 5 times in every 2 weeks, and the sera sample was
drawn one week after the final sensitization.
Groups II and III were sensitized according to the schedule modified from
the protocol of human leukemia treatment for dose and administration method
of NCS.
To group II, NCS 0.1 mg (0.04mg/kg/day) without any adjuvant for 4 con-
secutive days was given intramuscularly and repeatedly, and to group III the
same dose was given intravenouly as shown in Table 1.
NCS used experimentally and clinically in this study was supplied by
Kayaku Antibiotics Research Company. (Tokyo, Japan)
(2) Leukemia patients treated with NCS.
The investigated sera were drawn from 43 leukemia cases of various types
on several occasions after the repeated NCS administration. Cases were 19
acute myelogenous leukemia, 4 acute promyelocytic leukemia, 2 monocytic
leukemia, 1 erythroleukemia, 11 acute lymphocytic leukemia and 6 chronic
myelogenous leukemia in blast crisis.
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The method of administration of NCS, alone or in combination with con-
ventional antileukemic agents, was followed by the protocol; 2mg of NCS
daily for 4 consecutive days by intravenous drip infusion followed by 7-10 days
of pause. The same course trials have to be repeated until the remission crite-
ria will be satisfied.
The controls were sera of 14 healthy subjects and of 5 leukemia patients
without NCS administration.
(3) Passive hemagglutination (PHA) test by microplate method.
Anti-NCS antibody was examined by the passive hemagglutination test
and the hemagglutination inhibition test using the microplate method according
to Mukojima et al. (5). The NCS binding sheep red blood cell and the PHA
medium used in this experiment were the products of Nippon Kotai Kogyo
K.K.
(4) Passive cutaneous anaphylaxis (peA) reaction in guinea pigs.
Guinea pigs, weighing about 300-400g, of Hartley line, were divided into
6 groups, consisted of 3 in each.
The investigated sera were intradermally injected in the skin of shaved
dorsum; 0.1 ml of sera and adequately diluted sera with normal saline in
several grades were prepared.
Four hr after the above pre-treatment, the mixture of NCS (1 mg) and
normal saline (0.5ml) tinged with 1% Evans blue (totally 1.5ml) was injected
intravenously. Exactly 30min later, guinea pigs were sacrificed by head blow
and the dorsum was immediately skinned. The diameters of the pigmented
plaques at injected sites beneath the dorsal skin were measured.
RESULTS
(I) Anti-NCS antibody in rabbits by PHA test.
As shown in Table 2, in group I, the serum from No. I rabbit showed
the hemagglutination titer of 2 5 and No.2 rabbit achieved the titer up to 29 ,
which was sensitized with NOS mixed with Freund's complete adjuvant.
In group II, which received only NOS intramuscularly, No.4 rabbit showed
TABLE 2 HEMAGGLUTINATION TEST OF THE ANTI-NOS ANTIBODY IN RABBITS
Dilution (20 )
Group Rabbit 20 21 22 23 24 25 26 27 28 29 210
:1*1 + + + + + +
#2 + + + + + + + + + +
II #3 + +
#4 + + + + +
III #5 ±
#6 ±
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the titer of 24. But in group III, which received only NCS intravenously, the
sera showed no elevated titer of hemagglutination.
By the method of the hemagglutination inhibition test, in which the in-
vestigated sera were incubated with NOS for one hr to inactivate the effect of
antibody, the hemagglutinations were reversely inhibited, as shown in Table
3. And these results indicated that the above hemagglutinations were specific
to the presence of the anti-NCS antibody.
TABLE 3 HEMAGGLUTINATION INHIBITION TEST OF THE ANTI-NeS ANTIBODY IN RABBITS
Dilution (20 )
Rabbit 20 21 22 23 24 25 26 27 28 29 210
~2 control + + + + + + + + + +
inhibition + +
~4 control + + + + +
inhibition
~6 control
inhibition
(2) The investigation in leukemia patients treated with NCS, by PHA test screening.
Forty three leukemia cases were examL:e 1 totally 65 times. The total
amounts of NCS administered ranged 8 to 174 mg, and the total periods of NCS
administration ranged 4 to 87 days.
All of the investigated sera showed only the non-specific agglutination in
less than 23 dilution, and the questionable sera were confirmed by the hem-
aggluti~'ation inhibition test. Two cases, who showed the titer of 23 dilution,
were t,e p..tients S.T. and C.M., and their sera were re-examined by the
passiv~ cltaneous anaphylaxis reaction in guinea pigs, in the following experi-
ment.
(3) Anti-NCS antibody detection in sensitized rabbits and in leukemia patients by
PCA.
The results were shown in Table 4 and in Figures 1 and 2.
In group I, the established anti-NCS anti-serum of No.2 rabbit gave the
positive titer of 1 : 1000, dilution, and in group II, the result showed the titer
of 1 : 100 dilution by the serum of No.4 rabbit.
In 4 groups (III to VI), patients' sera were investigated to rule out the
presence of anti-NCS antibody. In groups IV and V, 2 patients (S.T. and C.M.)
were chosen because their sera had the titer of 23 dilution by PHA test. In
groups III and VI, other two patients (K.U. and N.L) were chosen because they
developed shock possibly due to the injection of NCS. K.U.'s serum was drawn
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TABLE 4 PASSIVE CUTANEOUS ANAPHYLAXIS (peA) REACTION OF THE ANTI-NCS
ANTIBODY IN GUINEA PIGS
139
Serum Dilution
Normal
1 : 1 1: 10 1: 100 1: 500 1: 1000 Saline
Group
I. Anti-NCS serum
of #2 rabbi t ttI+
II. Anti-NCS serum
of #4 rabbit +tt
III. Pt's serum (K.U.)
(S48. 12. 30)
IV. Pt's serum (S.T.)
(S5O. 5.24)
V. Pt's serum (C.M.)
(S49. 10.7)
VI. Pt's serum (N.I.)
(S5O. 4. 12)
+
++ +
Control Rabbit ~2
Normal Serum
Serum (1 : 1)
(i)
(ii)
(iii)
1tlt
(iii)
1tlt
(iii)
tttt
(iii)
1tlt
Criteria: Diameters averaged in each group
(-) no reaction (ttl IO-I5mm
(±) <5mm (+ttl15-20mm
(+) 5-lOmm (ttI+) >20mm
(i) #2 rabbit control serum
(ii) #4 rabbit control serum
(iii) normal human serum
Rabbit (112)
(:'\CS~ F. C. A .. L M.)
Fig. 1. PCA reaction of No.2 rabbit. Positive reac·
tion is seen up to the site of 1 : 1000 dil ution.
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Fig. 2. PCA reaction of pt. (K. U.). Negative reaction
is seen even in the site of I : I dilution. Control of NCS
antiserum is positive.
just on the day after the shock episode and N.I.'s serum was drawn on the next
day after the shock.
As shown in Table 4, there showed no presence of anti-NOS antibody at
all in the leukemia patients.
DISCUSSION
The antigenicity of NOS has been proved by this animal experiment and
by the papers reported previously.
And clinically, investigation of anti-NOS antibody in the patients treated
with enough amount of NCS has been carried out first time in this study.
L-asparaginase, which is an anti-tumor agent of high molecular protein
(molecular weight 100,000-160,000) and is refined from E. coli, caused the
antibody; this resulted in the loss of therapeutic effectiveness according to a
murine experiment (7).
Investigation of anti-L-asparaginase antibody during L-asparaginase the-
rapy in leukemia patients by the passive hemagglutination method showed the
high titer (1 : 1000-1 : 5000 dilution) in 14.8% patients (8).
And in another paper (9), the allergic phenomenon, s~ch as urticaria and
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fever, in a patient treated with L-asparaginase was proved to be related with
the IgG antibody production by PCA and radioimmunoelectrophoresis.
In this study, the anti-NCS antibody was produced easily in rabbits, when
NCS was given intramuscularly without any adjuvant. But in case of the
intravenous administration no antibody was detected.
This experimental result suggests that no antibody was detected at least by
PHA method in human leukemia cases, to whom NCS was administered intra-
venously and repeatedly.
The PCA reaction has been done to confirm the results of the PHA test.
The serum of No.2 rabbit had the titer of 29 (= 1 : 512 dilution) by PHA
and was related with the titer of 1 : 1000 dilution by PCA. Similarly the
serum of No.4 rabbit had the titer of 24 (= 1 : 16 dilution) by PHA and the
titer of 1 : 100 dilution by PCA. A slight dissociation between the titer of
PHA and that of PCA is considered to be due to more sensitive PCA than PHA
for the detection of a very small quantity of IgG antibody.
The negative data of two cases (K.U. and N.L) are important to rule out
the possibility of anaphylactic reaction due to NCS antibody clinically. As these
two patients have never been in shock again up to now with other various
medications, still NCS is thought to be a causative agent for shock, although
the shock episodes in these two cases were successfully treated with medical
procedures. These data can rule out the interference of NCS antibody for the
possible anaphylaxis and other adverse reactions in leukemia patients.
The reasons of no detectable antibody production by intravenous administ-
ration of NCS can be discussed as follows. (i) NCS is rapidly excreted in urine
and the concentration level in blood is decreased, when NCS is given by intra-
venous route (10). (ii) NCS has the immunosuppressive effect on the antibody
production (11). (iii) Most of the conventional antileukemiC agents in combina-
tion with NCS, when treating the human leukemia, have the immunosup-
pressive effects as well. (iv) The immuno-surveillance system is considered to be
generally depressed in leukemia patients, especially of the acute phase.
Although the production of antibody against the antileukemic antibiotic is
the interesting phenomenon in experimental work, the clinical analysis of anti-
body detection should be investigated by further studies. The anaphylactic
reactions in human, which is proved to be due to the antibody production
against NCS, has not been found yet, and the hypersensitivity against NCS is
considered to be only a factor causing this rare, undesirable reaction.
Acknowledgments. I would like to acknowledge the careful review, comments and sugges-
tions made by Prof. Kiyoshi Hiraki and Dr. Koichi Kitajima.
7
Toki: Absence of anti-neocarzinostatin (NCS) antibody production in
Produced by The Berkeley Electronic Press, 1976
142 H. TOKI
REFERENCES
1. Ishida, N., Miyazaki, K., Kumagai, K. and Rikimaru, M.: Neocarzinostatin, and anti-
tumor antibiotic of high molecular weight; isolation, physiochemical properties and
biological activities. j. Antibiot. Ser. A. 18, 68-76, 1965 (in Japanese).
2. Meienhofer,]., Maeda, H., Glaser, C. B., Czombos, J. and Kuromizu, K.: Primary Struc-
ture of Neocarizinostatin, an Antitumor Protein. Science 24, 875-876, 1972.
3. Hiraki, K., Kitajima, K., Nagao, T., Takahashi,1., Kinoshita, H., Kamimura,O., Haya-
shi, H., Moriwaki, Y. and Chen, P.: A new chemotherapy of acute leukemia with "Neo-
carzinostatin". Igaku-no-ayumi 87, 18-19, 1973 (in Japanese).
4. Kitajima, K., Nagao, T., Takahashi,1., Kamimura,O., Toki, H., Chen, P., Naito, T.,
Nakanishi, N., Hayashi, H., Niiya, K., Muguruma, M. and Sanada, H.: Multicombina-
tion Chemotherapy of Acute Leukemia with Neocarzinostatin and Other Conventional
Antileukemic Agents. Cancer and Chemotherapy, 2, 65-71, 1975 (in Japanese).
5. Mukojima, T. and Kimura, K.: Immunoassay of Neocarzinostatin. jpn. j. Cancer Clin.
20, 246-248, 1974 (in Japanese).
6. Tsujino, M., Matsumoto, S., Kikuchi, M. and Ishida, N.: Antigenicity of Neocarzino-
statin, a high molecular antitumor agent. Igaku-no-ayumi 91,341-343, 1974 (in Japanese).
7. Baechtel, S. and Prager, M. D.: Basis for Loss of Therapeutic Effectiveness of L-Aspa-
raginase in Sensitized Mice. Cancer Res. 33, 1966-1969, 1973.
8. Yamada, K., Hirano, M., Kakisawa, H., Morita, A., Uetani, T., Ono, R., Kawashima,
K., Takahashi, T., Nishiwaki, H., Sako, F., Koie, K., Kamiya, T., Horikoshi, N. and
Miura, M.: Studies on Antileukemic Action of L-Asparaginase. Saishin-igaku 25, 1064-
1068, 1970 (in Japanese).
9. Ueda, E., Yagura, T., Tsubura, E. and Yamamura, Y.: A case of reticulum cell sarcoma
treated with L-asparaginase. j pn. j. Cancer Clin. 16, 1122-1127, 1970 (in Japanese) .
10. Fujita, H., Nakayama, N., Sawabe, T. and Kimura, K.: in vivo distribution and inacti-
vation of Neocarzinostatin. jap. j. of Antibiotics 111-5.6,471-478, 1970 (in Japanese).
11. Takahashi, 1., Mikochi, H., Sakato,]., Nakanishi, T., Toki, H., Kamimura, O. and Kita-
jima, K.: Effect of Neocarzinostatin on Hemolytic Plaque-Forming Cell Production in
Mice. Acta Med. Okayama 29, 327-328, 1975.
8
Acta Medica Okayama, Vol. 30 [1976], Iss. 2, Art. 7
http://escholarship.lib.okayama-u.ac.jp/amo/vol30/iss2/7
